Loading data for ENTX — first visit, this takes a few seconds.
Entera Bio Ltd. (ENTX)
NasdaqCM: ENTX
· Real-Time Price · USD
3.03
-0.05 (-1.62%)
At close: Aug 31, 2026, 2:25 PM
The price, the headline numbers and the latest news, in one place.
Entera Bio Ltd. (ENTX) Stock Price, Analysis & Data
-1.62% (1D)
No data available
| Bid | 2.27 |
| Market Cap | 509.04M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -17.03M |
| 1.40 | |
| -0.35 | |
| n/a | |
| -5.35 | |
| P/B (ttm) | 20.00 |
| P/S (ttm) | n/a |
| Earnings Date | n/a |
| Ask | 3.05 |
| Volume | 138,022 |
| Avg. Volume (20D) | 2,581,785 |
| Open | 3.12 |
| Previous Close | 3.08 |
| Day's Range | 3.00 - 3.15 |
| 52-Week Range | 0.91 - 4.20 |
| Analyst | n/a |
| Price Target | n/a |
| Dividends | n/a |
| Ex-Dividend Date | n/a |
About ENTX
Entera Bio Ltd., a clinical stage company, engages in the development of oral peptides and protein replacement therapies in Israel and internationally. It develops EB613, an oral teriparatide, which completed the Phase II clinical trial for the treatment of osteoporosis and Phase I clinical trial for the treatment of stress fractures. The company is also involved in the development of EB612, a tablet peptide replacement therapy, which is in Phase...
Industry Biotechnology
Sector Healthcare
IPO Date Jun 28, 2018
Employees 20
Stock Exchange NasdaqCM
Ticker Symbol ENTX
Website https://enterabio.com
Financial Performance
In 2025, Entera Bio's revenue was 42K, a decrease of -76.8% compared to the previous year's 181K. Earnings were -11.44M, an increase of 19.89%.
Financial StatementsEarnings Surprise
Entera Bio has released their quarterly earnings on Aug 7, 2026:
- Revenue of $0 misses estimates by $0, with NaN% YoY growth.
- EPS of -0.14 misses estimates by -0.06, with -133.33% YoY decline.
3 weeks ago · InvestorsHub
Entera Bio shares slip as Q2 loss comes in wider than expectedEntera Bio Ltd. (NASDAQ:ENTX) shares fell 1.
Page 1 of 2